Nurix Q2 Loss Widens to $89.5M; Cash at $443.5M, Pro-Forma $1.14B with Roche Deal

summarizeSummary

Nurix posted a wider Q2 net loss of $89.5M but holds $443.5M in cash, with pro-forma cash of ~$1.14B including the expected Roche upfront. R&D spending rose as the bexobrutideg Phase 2 trial advances.

check_boxKey Events · Earnings and Guidance · NRIX

• Q2 Net Loss Widens to $89.5M

  Net loss increased to $89.5M from $43.5M a year ago, driven by a 12% rise in R&D expenses to $87.7M and lower collaboration revenue of $9.0M vs. $44.1M.

• Cash Position Remains Strong

  Cash, equivalents, and marketable securities totaled $443.5M as of May 31, 2026. Pro-forma cash, including the expected $700M Roche upfront, is approximately $1.14B, funding operations well beyond 12 months.

• R&D Spending Driven by Bexobrutideg

  External clinical costs for bexobrutideg (NX-5948) rose to $28.2M in Q2 from $18.6M a year ago, reflecting accelerated enrollment in the Phase 2 trial.

• Sanofi Collaboration Amended

  The Seventh Amendment allows Sanofi to continue research on STAT6 and an additional target after the original research term, with no immediate revenue impact.

auto_awesomeAnalysis · NRIX · Life Sciences

A wider Q2 net loss of $89.5 million, driven by lower collaboration revenue, was offset by a strong cash position of $443.5 million. When the expected $700 million Roche upfront payment is included, pro-forma cash reaches approximately $1.14 billion, extending the runway well beyond 12 months. R&D spending jumped 12% to $87.7 million, fueled by the bexobrutideg Phase 2 trial. The company also amended its Sanofi collaboration to allow continued research on STAT6 and another target. Against the backdrop of the recent Roche deal and positive clinical data, the financials show a company investing heavily in its lead asset while maintaining a strong cash position.